Fast Five Quiz: Management of Chronic Kidney Disease Anemia

Pradeep Arora, MD


April 19, 2022

HIF-PHIs are molecular inhibitors of prolyl hydroxylase domain dioxygenases, which stimulate hypoxic induction, resulting in increased erythropoietin production and iron metabolism. Recent data from phase 2 and phase 3 studies have demonstrated the efficacy of HIPreF-PHIs in correcting and maintaining hemoglobin levels with fewer adverse cardiovascular effects as compared with ESAs in patients with CKD. Currently, several HIF-PHIs are being marketed in Asia. However, questions and concerns remain and warrant further investigation.

Preclinical and clinical studies have suggested that inhibitors of hepcidin may be beneficial for anemia in CKD, but to date, no compounds are under investigation in humans.

Learn more about CKD anemia management.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.